This pharmaceutical executive and attorney offers expert witness services with over 25 years of experience in intellectual property, drug development, regulatory affairs, and pharmaceutical strategy. Their background spans biotechnology, medical devices, vaccines, and biosimilars, supporting legal analysis in matters involving patent rights, FDA regulation, licensing structures, and regulatory compliance. Their work is grounded in experience developing and implementing intellectual property strategies and regulatory frameworks across public and private sector environments.

Their practice encompasses intellectual property and patent-related matters, including patent analysis, licensing, and disputes involving pharmaceutical and biotechnology assets. This includes structuring and negotiating licensing agreements, advising on intellectual property considerations in connection with acquisitions, and addressing cross-border regulatory and commercialization considerations. Their experience in regulatory affairs and compliance also includes drug development and registration processes, oversight of approval pathways, and alignment with FDA and international regulatory standards governing vaccines, biosimilars, and medical devices.

Their work in pharmaceutical development and global initiatives includes participation in drug approval efforts, vaccine development programs, and biosimilar market activities, as well as evaluation of regulatory and commercial factors influencing product viability. Their involvement with organizations such as the World Health Organization and CEPI reflects engagement in international public health initiatives, pharmaceutical investment considerations, and collaborative development efforts across regulatory jurisdictions. This expert holds a Juris Doctor, a Master of Arts in Clinical and Developmental Psychology, and a Bachelor of Arts in European History, and is admitted to the New York Bar.